GET DAILY SIGNALSMDxHealth (MDXH) Shares Slide -77% Over 30 Days on Revenue Shortfall and Guidance Pause
Key Takeaways
- MDxHealth (MDXH) shares fell roughly 77% over the last 30 days, dropping from about $0.60 to approximately $0.14, after the company pre-announced disappointing third-quarter revenue and suspended its full-year guidance.
- The sharpest decline occurred in mid-October, when preliminary Q3 2026 revenue of $22.7 million fell short of expectations and triggered heavy selling volume.
- Several analysts downgraded the stock in the aftermath, including moves to Hold/Neutral from Buy ratings, reflecting reduced confidence in near-term execution.
- Over the last quarter, the stock has declined roughly 80%, extending a longer downtrend driven by revenue shortfalls, guidance cuts, and balance-sheet and listing-compliance concerns.
- The company's third-quarter 2026 earnings report, scheduled for November 12, is the next major catalyst investors are watching closely.
- Ongoing Nasdaq compliance issues related to minimum market value and bid price requirements add another layer of uncertainty to the stock's outlook.
MDxHealth (MDXH) Company Overview and Market Position
MDxHealth SA is a commercial-stage precision diagnostics company headquartered in Herstal, Belgium, with its shares trading on the Nasdaq as American Depositary Receipts. The company focuses on urology, particularly prostate cancer diagnostics. Its portfolio includes the Confirm mdx epigenetic tissue test, the ExoDx non-invasive urine test for prostate cancer risk assessment, and the Genomic Prostate Score (GPS), which provides genomic insights to guide prostate cancer diagnosis and treatment decisions. The company previously offered a Resolve mdx test for urinary tract infections but has since discontinued that business line. MDxHealth sells through a direct urology sales force, and investors follow the stock primarily for its revenue-growth trajectory, path toward profitability, and expansion of its precision diagnostics franchise.
MDxHealth (MDXH) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MDXH shares fell from approximately $0.60 to about $0.14, a decline of roughly 77%. The move was not gradual: the stock traded near $0.60 through mid-October before collapsing in a single session, when the closing price dropped from around $0.60 to roughly $0.21 on exceptionally high volume. The stock continued to drift lower in the following weeks, reaching its 52-week low near $0.14. I also checked this using Tickeron’s AI Pattern Search Engine to confirm the timing of the volume spike.
The last quarter tells a similarly negative story. From levels near $0.70 to $0.72 in August, the stock has fallen roughly 80% into early November. This sustained downtrend reflects repeated revenue shortfalls, downward guidance revisions, and mounting concerns about dilution and Nasdaq listing compliance, rather than a single isolated event.
What Drove MDXH Stock Price in the Last 30 Days
The primary catalyst was the company's October 15 announcement of preliminary third-quarter 2026 revenue of approximately $22.7 million, which came in below expectations. More significantly, MDxHealth suspended its full-year 2026 revenue guidance, removing a key benchmark that investors had relied on. Management attributed the weakness to unexpected challenges in its diagnostics volumes, and the pre-announcement triggered a wave of analyst downgrades, including moves to Hold from Buy at Craig-Hallum and Lake Street and to Neutral from Buy at BTIG.
The suspension of guidance signaled reduced visibility into the company's growth and undermined confidence that its diagnostics franchise could scale toward profitability on the prior timeline. Combined with concerns about share dilution from earlier capital raises and Nasdaq notifications regarding minimum market value and bid price deficiencies, the news drove a sharp repricing of the stock. The result was one of the steepest single-session declines in the company's recent history, followed by continued selling pressure into November.
What Drove MDXH Stock Performance Over the Last Quarter
Beyond the October pre-announcement, the broader quarterly decline reflects a multi-month deterioration in sentiment. Earlier in 2026, the company had already lowered its full-year revenue outlook from a range of $137 million to $140 million down to $110 million to $115 million, signaling slower-than-expected adoption of its diagnostic tests. A registered direct placement that sold millions of new shares raised capital but diluted existing holders and pushed some analysts to trim their price targets.
Added to this, MDxHealth received Nasdaq notification letters concerning minimum market value and minimum bid price requirements, highlighting the pressure on the stock and the company's need to regain compliance. The combination of guidance cuts, dilution, listing concerns, and a still-unprofitable operating model has kept the stock under sustained pressure throughout the quarter, even as the company has continued to report double-digit year-over-year revenue growth.
MDXH Stock Forecast Drivers: What Investors Should Watch Next
The most immediate event is the company's third-quarter 2026 earnings report and conference call, scheduled for November 12, 2026. Investors will focus on actual revenue results, gross margins, operating losses, cash position, and any refreshed or reinstated guidance. Commentary on sales-force productivity, adoption of the ExoDx and GPS tests, and the timeline to profitability will be closely scrutinized.
Beyond earnings, key watch items include the company's ability to resolve its Nasdaq listing compliance notices, whether it pursues additional capital raises that could further dilute shareholders, and any signs of stabilization in diagnostic test volumes. Macroeconomic conditions affecting healthcare utilization and reimbursement also remain relevant. These factors will shape whether MDXH can rebuild investor confidence or face continued pressure on its valuation.
Using AI Tools for Deeper Analysis
From what I see in the data, tools like Tickeron’s AI Trend Prediction Engine help me cross-check sentiment shifts and pattern formations across similar healthcare names. I find it useful for spotting how algorithmic models interpret the same catalysts that move individual stocks like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDXH's Stochastic Oscillator sits in oversold zone for 16 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for MDXH just turned positive on November 06, 2026. Looking at past instances where MDXH's MACD turned positive, the stock continued to rise in 22 of 30 cases over the following month. The odds of a continued upward trend are 73%.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXH advanced for three days, in 96 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
MDXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXH as a result. In 39 of 50 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
MDXH moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MDXH entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.641) is normal, around the industry mean (67.298). P/E Ratio (0.000) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. MDXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement